RET-altered cancer

FDA approves Ellipses’ application for advanced RET-altered cancer treatment
Pharmaceutical Business Review
Thu, 06/23/22 - 10:52 am
Ellipses Pharma
EP0031
FDA
RET-altered cancer
Roche, Blueprint Medicines sign $1.7bn worth deal for pralsetinib
Pharmaceutical Business Review
Tue, 07/14/20 - 10:29 am
Roche
Blueprint Medicines
pralsetinib
RET-altered cancer
ASCO data for Blueprint's BLU-667 competitive with Lilly's LOXO-292 in RET-altered cancers
BioCentury
Mon, 06/3/19 - 11:25 am
Blueprint Medicines
BLU-667
ASCO 2019
Eli Lilly
RET-altered cancer
LOXO-292